What is the difference between Mounjaro and Zepbound for Medicare coverage?

Mounjaro is FDA-approved for type 2 diabetes and is covered under Part D for that indication. Zepbound uses the same active ingredient (tirzepatide) but is approved for chronic weight management. Medicare's GLP-1 Bridge program and expanded coverage rules may allow Zepbound coverage for qualifying beneficiaries. Verify with your plan.

How much does Mounjaro cost with Medicare?

With an approved prior authorization, Medicare Part D members pay their plan's copay or coinsurance rather than the full cash price (which often exceeds $1,000/month). The exact amount depends on your plan's formulary tier and the Part D benefit phase.

Does Medicare cover Mounjaro for weight loss?

Generally no. Part D does not cover Mounjaro when prescribed solely for weight loss. Zepbound (tirzepatide for obesity) may be covered under expanded Medicare GLP-1 Bridge rules for qualifying beneficiaries. See CMS.gov for current guidance.

Does Medicare Cover Mounjaro (Tirzepatide) in 2026?

Q: Does Medicare cover Mounjaro?

Yes. Medicare Part D covers Mounjaro (tirzepatide) when prescribed for type 2 diabetes. Prior authorization is required. It is generally not covered when prescribed for weight loss alone.

Mounjaro is covered by Medicare Part D for type 2 diabetes — but not for weight loss. Here's how coverage works, what prior auth requires, and how it differs from Zepbound.

By Alex Carter, Medicare benefits specialist · Published June 28, 2026 · Reviewed June 28, 2026

Mounjaro (tirzepatide, made by Eli Lilly) is a dual GIP/GLP-1 receptor agonist — a newer class of medication that targets two hormones instead of one, delivering stronger blood sugar control and weight loss than earlier GLP-1 drugs. Since its FDA approval for type 2 diabetes in 2022 and its surge in prescriptions, Medicare beneficiaries have been asking the same question: will my Part D plan pay for it? The answer is yes — under the right conditions.

The quick answer

Medicare Part D covers Mounjaro when prescribed for type 2 diabetes. It is generally not covered for weight loss alone. Prior authorization is required by nearly all plans. Its twin drug, Zepbound (same molecule, approved for obesity), may be covered for qualifying beneficiaries under expanded Medicare GLP-1 rules.

Mounjaro vs. Zepbound: same drug, different coverage

Tirzepatide is sold under two brand names for two different FDA-approved uses. Mounjaro is approved to improve blood sugar control in adults with type 2 diabetes. Zepbound is approved for chronic weight management in adults with obesity (BMI ≥ 30) or overweight (BMI ≥ 27) with at least one weight-related condition. You can verify both sets of approved uses on FDA.gov.

For Medicare, the distinction matters a great deal. Part D has historically paid for conditions, not for weight loss alone. That means Mounjaro — for diabetes — has a clear coverage pathway. Zepbound — for obesity — has a more complex one, tied to evolving CMS rules about the Medicare GLP-1 Bridge program. See our covered drugs page for a full comparison.

When does Medicare cover Mounjaro?

Mounjaro — covered

Type 2 diabetes — the approved indication and the primary Medicare Part D pathway.
Plans may also cover it under other medically necessary circumstances — check your formulary.

Mounjaro — not covered

Weight loss alone — no diabetes or other qualifying medical indication means most plans will deny it.
Off-label uses without an approved FDA indication are unlikely to pass PA.

Source: FDA.gov; CMS.gov. Coverage is illustrative; verify with your plan.

Prior authorization for Mounjaro

Virtually every Part D plan requires prior authorization before covering Mounjaro. Your prescriber typically submits documentation of your type 2 diabetes diagnosis, a recent A1C value, and in some cases evidence that you tried another diabetes medication first (step therapy). Plans often apply step therapy for newer, high-cost drugs in this class — meaning your plan may ask you to try metformin or another first-line agent before approving Mounjaro.

The plan must respond within 72 hours for a standard request, or 24 hours for an expedited one. If denied, you can appeal through Medicare's coverage determination process. Read our prior authorization denied guide for the full appeal path.

What does Mounjaro cost with Medicare?

Without insurance, Mounjaro's list price is more than $1,000 per month. With an approved prior authorization under Part D, you pay your plan's copay or coinsurance for the tier where Mounjaro sits on the formulary — often in the $50–$200 range depending on your plan and benefit phase, though your exact cost will differ.

The Inflation Reduction Act's out-of-pocket cap for covered Part D drugs applies here as well. Once you hit the annual cap (see the current amount at CMS.gov), you pay $0 for covered drugs through the end of the year. Use our cost calculator to estimate your annual out-of-pocket.

What about Zepbound for Medicare beneficiaries?

If your goal is weight management rather than diabetes control, Zepbound (tirzepatide for obesity) is the relevant drug. Coverage under traditional Part D for weight loss alone has been limited, but CMS has been expanding access through the Medicare GLP-1 Bridge program for qualifying beneficiaries. Eligibility depends on your specific conditions and plan. Run our eligibility check to see which pathway applies to you.

Find out if you qualify for coverage

The eligibility check takes about a minute and identifies the right Medicare coverage pathway for your situation.

Check my eligibility →